PRESS RELEASE published on 03/27/2024 at 11:30, 6 months 1 day ago Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials Moderna announces successful clinical readouts for fourth respiratory vaccine candidate meeting Phase 3 endpoints and provides updates on vaccine portfolios, clinical trials, and financial agreements at fifth Vaccines Day event Clinical Trials Moderna Vaccine Phase 3 Respiratory
BRIEF published on 03/26/2024 at 12:05, 6 months 2 days ago Moderna Reports Positive Results in Phase 3 Trial of New COVID-19 Vaccine Public Health COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283
PRESS RELEASE published on 03/26/2024 at 12:00, 6 months 2 days ago Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine Moderna's mRNA-1283 shows higher immune response than mRNA-1273.222 in Phase 3 trial. Next-generation vaccine offers longer shelf life and storage benefits, paving way for flu-COVID combo vaccine, mRNA-1083 COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 MRNA-1273.222
BRIEF published on 02/29/2024 at 13:00, 6 months 28 days ago Moderna Announces Fifth Annual Vaccine-Focused Investor Event Investors Webcast Moderna Investor Event MRNA Vaccines
PRESS RELEASE published on 02/29/2024 at 13:00, 6 months 28 days ago Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024 Moderna, Inc. announces its fifth annual Investor Event focusing on vaccines and business updates on March 27, 2024. Presentation at 9:00 a.m. ET. Live webcast available on the Moderna website Webcast MRNA Medicine Moderna Investor Event MRNA Vaccines
BRIEF published on 02/28/2024 at 13:00, 7 months ago Moderna announces participation in investor conferences Investor Conferences Webcast MRNA Technology Moderna Health
PRESS RELEASE published on 02/28/2024 at 13:00, 7 months ago Moderna to Present at Upcoming Investor Conferences in March 2024 Moderna, Inc. to participate in upcoming investor conferences and showcase advancements in mRNA technology. Visit investors.modernatx.com for webcast details Investor Conferences Healthcare Moderna Inc. MRNA Technology COVID-19 Vaccines
BRIEF published on 02/22/2024 at 12:30, 7 months 6 days ago Moderna announces mixed financial results for 2023 and optimistic outlook for 2024 2023 Financial Results 2024 Forecasts Moderna RSV Vaccine Research Pipeline
PRESS RELEASE published on 02/22/2024 at 12:30, 7 months 6 days ago Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates Moderna, Inc. reports Q4 revenues of $2.8 billion with a GAAP net income of $217 million. Expects regulatory approvals for RSV vaccine and forecasts 2024 product sales of $4 billion Financial Results Moderna Inc. RSV Vaccine Product Sales Regulatory Approvals
PRESS RELEASE published on 02/07/2024 at 06:00, 7 months 21 days ago Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering Moderna, Inc.'s CEO Stéphane Bancel elected to National Academy of Engineering for distinguished contributions to engineering and manufacturing of pharmaceutical products, including COVID-19 vaccine. Company has 45 mRNA therapeutic and vaccine programs in pipeline Moderna Inc COVID-19 Vaccine Stéphane Bancel National Academy Of Engineering MRNA Technology
Published on 09/28/2024 at 02:06, 18 hours 56 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 19 hours 2 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 20 hours 52 minutes ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 7 hours 1 minute ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 22 hours 32 minutes ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 23 hours 5 minutes ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 2 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 2 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 3 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 3 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 3 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 3 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024